1043 related articles for article (PubMed ID: 19022318)
1. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.
Van Damme P; Oosterhuis-Kafeja F; Van der Wielen M; Almagor Y; Sharon O; Levin Y
Vaccine; 2009 Jan; 27(3):454-9. PubMed ID: 19022318
[TBL] [Abstract][Full Text] [Related]
2. Dose sparing with intradermal injection of influenza vaccine.
Kenney RT; Frech SA; Muenz LR; Villar CP; Glenn GM
N Engl J Med; 2004 Nov; 351(22):2295-301. PubMed ID: 15525714
[TBL] [Abstract][Full Text] [Related]
3. Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination.
Sugimura T; Ito Y; Tananari Y; Ozaki Y; Maeno Y; Yamaoka T; Kudo Y
Vaccine; 2008 May; 26(22):2700-5. PubMed ID: 18436353
[TBL] [Abstract][Full Text] [Related]
4. Antibody responses after dose-sparing intradermal influenza vaccination.
Auewarakul P; Kositanont U; Sornsathapornkul P; Tothong P; Kanyok R; Thongcharoen P
Vaccine; 2007 Jan; 25(4):659-63. PubMed ID: 17011678
[TBL] [Abstract][Full Text] [Related]
5. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain.
Hung IF; Levin Y; To KK; Chan KH; Zhang AJ; Li P; Li C; Xu T; Wong TY; Yuen KY
Vaccine; 2012 Oct; 30(45):6427-35. PubMed ID: 22910287
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration.
Künzi V; Klap JM; Seiberling MK; Herzog C; Hartmann K; Kürsteiner O; Kompier R; Grimaldi R; Goudsmit J
Vaccine; 2009 Jun; 27(27):3561-7. PubMed ID: 19464535
[TBL] [Abstract][Full Text] [Related]
7. The immunogenicity of intradermal influenza vaccination in COPD patients.
Chuaychoo B; Wongsurakiat P; Nana A; Kositanont U; Maranetra KN
Vaccine; 2010 May; 28(24):4045-51. PubMed ID: 20412877
[TBL] [Abstract][Full Text] [Related]
8. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
9. Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer.
Jo YM; Song JY; Hwang IS; Lee J; Oh SC; Kim JS; Kim SR; Kim WJ; Cheong HJ
J Med Virol; 2009 Apr; 81(4):722-7. PubMed ID: 19235853
[TBL] [Abstract][Full Text] [Related]
10. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G
Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults.
Chi RC; Rock MT; Neuzil KM
Clin Infect Dis; 2010 May; 50(10):1331-8. PubMed ID: 20377407
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children.
Chiu SS; Peiris JS; Chan KH; Wong WH; Lau YL
Pediatrics; 2007 Jun; 119(6):1076-82. PubMed ID: 17545373
[TBL] [Abstract][Full Text] [Related]
13. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
[TBL] [Abstract][Full Text] [Related]
14. Serum antibody responses after intradermal vaccination against influenza.
Belshe RB; Newman FK; Cannon J; Duane C; Treanor J; Van Hoecke C; Howe BJ; Dubin G
N Engl J Med; 2004 Nov; 351(22):2286-94. PubMed ID: 15525713
[TBL] [Abstract][Full Text] [Related]
15. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
Gorse GJ; Falsey AR; Fling JA; Poling TL; Strout CB; Tsang PH
Vaccine; 2013 May; 31(19):2358-65. PubMed ID: 23499604
[TBL] [Abstract][Full Text] [Related]
16. Response to a monovalent 2009 influenza A (H1N1) vaccine.
Greenberg ME; Lai MH; Hartel GF; Wichems CH; Gittleson C; Bennet J; Dawson G; Hu W; Leggio C; Washington D; Basser RL
N Engl J Med; 2009 Dec; 361(25):2405-13. PubMed ID: 19745216
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
Tsang P; Gorse GJ; Strout CB; Sperling M; Greenberg DP; Ozol-Godfrey A; DiazGranados C; Landolfi V
Vaccine; 2014 May; 32(21):2507-17. PubMed ID: 24120672
[TBL] [Abstract][Full Text] [Related]
18. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial.
Holland D; Booy R; De Looze F; Eizenberg P; McDonald J; Karrasch J; McKeirnan M; Salem H; Mills G; Reid J; Weber F; Saville M
J Infect Dis; 2008 Sep; 198(5):650-8. PubMed ID: 18652550
[TBL] [Abstract][Full Text] [Related]
19. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults.
Leroux-Roels I; Vets E; Freese R; Seiberling M; Weber F; Salamand C; Leroux-Roels G
Vaccine; 2008 Dec; 26(51):6614-9. PubMed ID: 18930093
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older.
Kerzner B; Murray AV; Cheng E; Ifle R; Harvey PR; Tomlinson M; Barben JL; Rarrick K; Stek JE; Chung MO; Schödel FP; Wang WW; Xu J; Chan IS; Silber JL; Schlienger K
J Am Geriatr Soc; 2007 Oct; 55(10):1499-507. PubMed ID: 17908055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
